SFCM
CLYM

Seven Fleet Capital Management’s Climb Bio CLYM Stock Holding History

Seven Fleet Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130,654
Closed -$895K – 119
2026
Q1 		$895K Buy
130,654
+54,254
+71% +$313K 0.28% 65
2025
Q4 		$306K Buy
+76,400
New +$183K 0.21% 58

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Seven Fleet Capital Management's CLYM Position: Q2 2026 in Review

Seven Fleet Capital Management sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 130,654 shares — an estimated $895K sold.

Seven Fleet Capital Management first reported a position in CLYM in Q4 2025 and held it in 2 quarters. The position peaked at $895K in Q1 2026. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Seven Fleet Capital Management reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
  • Seven Fleet Capital Management sold 130,654 Climb Bio shares in Q2 2026, an estimated $895K.
  • Seven Fleet Capital Management first reported a position in Climb Bio in Q4 2025 and held it in 2 quarters.
  • Seven Fleet Capital Management's Climb Bio position peaked at $895K in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.